Surface Modification of Biomaterials: A Quest for Blood Compatibility

UCL Centre for Nanotechnology & Regenerative Medicine, University College London, Pond Street, London NW3 2QG, UK.
International Journal of Biomaterials 05/2012; 2012:707863. DOI: 10.1155/2012/707863
Source: PubMed

ABSTRACT Cardiovascular implants must resist thrombosis and intimal hyperplasia to maintain patency. These implants when in contact with blood face a challenge to oppose the natural coagulation process that becomes activated. Surface protein adsorption and their relevant 3D confirmation greatly determine the degree of blood compatibility. A great deal of research efforts are attributed towards realising such a surface, which comprise of a range of methods on surface modification. Surface modification methods can be broadly categorized as physicochemical modifications and biological modifications. These modifications aim to modulate platelet responses directly through modulation of thrombogenic proteins or by inducing antithrombogenic biomolecules that can be biofunctionalised onto surfaces or through inducing an active endothelium. Nanotechnology is recognising a great role in such surface modification of cardiovascular implants through biofunctionalisation of polymers and peptides in nanocomposites and through nanofabrication of polymers which will pave the way for finding a closer blood match through haemostasis when developing cardiovascular implants with a greater degree of patency.


Available from: Brian G Cousins, May 30, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular implants find wide clinical applications, making a great contribution to the treatment of cardiovascular diseases. Such devices, endovascular stents, artificial vascular grafts, prosthetic heart valves to name a few typical examples, have been the mainstay of cardiovascular surgery. However, failure cases of the implants still exist, which urge us to understand what has happened at the blood-contacting interface and how the tissues have responded during the post-implantation period. Aiming to eliminate these pathological events, various approaches of surface modification of the cardiovascular devices have been used in order to improve hemocompatibility and cytocompatibility. In this review, the blood-biomaterial interfacial events and the evolution of the surface modification strategies are discussed, together with the recent developments on the surface modification of cardiovascular materials like biomimetic extracellular matrix and accelerated endothelialization. These novel surface modification strategies open a new chapter on designing ideal blood-friendly implantable materials. (C) 2013 Published by Elsevier B.V.
    Surface and Coatings Technology 10/2013; 233:80-90. DOI:10.1016/j.surfcoat.2013.02.008 · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the thrombogenic nature of the surfaces of cardiovascular devices is an important aspect of blood biocompatibility, few studies have examined platelet deposition onto opaque materials used for these devices in real time. This is particularly true for the metallic surfaces used in current ventricular assist devices (VADs). Using hemoglobin depleted red blood cells (RBC ghosts) and long working distance optics to visualize platelet deposition, we sought to perform such an evaluation. Fluorescently labeled platelets mixed with human RBC ghosts were perfused across 6 opaque materials (a titanium alloy (Ti6Al4V), silicon carbide (SiC), alumina (Al2O3), 2-methacryloyloxyethyl phosphorylcholine polymer coated Ti6Al4V (MPC-Ti6Al4V), yttria partially stabilized zirconia (YZTP), and zirconia toughened alumina (ZTA)) for 5 min at wall shear rates of 400 and 1000 sec-1. Ti6Al4V had significantly increased platelet deposition relative to MPC-Ti6Al4V, Al2O3, YZTP, and ZTA at both wall shear rates (P <0.01). For all test surfaces, increasing the wall shear rate produced a trend of decreased platelet adhesion. The described system can be a utilized as a tool for comparative analysis of candidate blood-contacting materials with acute blood contact.
    Journal of Biomedical Materials Research Part A 04/2015; 103(4). DOI:10.1002/jbm.a.35202 · 2.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is the dominant cause of mortality in developed countries, with coronary artery disease (CAD) a predominant contributor. The development of stents to treat CAD was a significant innovation, facilitating effective percutaneous coronary revascularization. Coronary stents have evolved from bare metal compositions, to incorporate advances in pharmacological therapy in what are now known as drug eluting stents (DES). Deployment of a stent overcomes some limitations of balloon angioplasty alone, but provides an acute stimulus for thrombus formation and promotes neointimal hyperplasia. First generation DES effectively reduced in-stent restenosis, but profoundly delay healing and are susceptible to late stent thrombosis, leading to significant clinical complications in the long term. This review characterizes the development of coronary stents, detailing the incremental improvements, which aim to attenuate the major clinical complications of thrombosis and restenosis. Despite these enhancements, coronary stents remain fundamentally incompatible with the vasculature, an issue which has largely gone unaddressed. We highlight the latest modifications and research directions that promise to more holistically design coronary implants that are truly biocompatible.
    Materials 12/2013; 7(2). DOI:10.3390/ma7020769 · 1.88 Impact Factor